To strengthen our findings, we demonstrated in a proof-of-concept study that pharmacological blockade of the IGFBP3/TMEM219 signaling/binding with ecto-TMEM219 successfully improved the signs and symptoms of colitis in a T cell adoptive transfer model, which better parallels the pathogenesis of CD. The gene discussed is IGFBP3; the disease is colitis.